Results 31 to 40 of about 4,078 (132)

Long-Term Survival and Value of ¹⁸F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with ¹⁷⁷Lu-DOTATATE

Life, 2021
Peptide receptor radionuclide therapy (PRRT) has been recognized as a promising therapy against neuroendocrine tumors (NETs). The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in NETs has been a matter of controversy.
Margarida Rodrigues, Kevin-Klaus Winkler, Hanna Svirydenka, Bernhard Nilica, Christian Uprimny, Irene Virgolini   +5 more
doaj   +1 more source

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Diagnostics, 2013
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via ...
Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky   +8 more
doaj   +1 more source

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy

Frontiers in Endocrinology
BackgroundPeptide receptor radionuclide therapy (PRRT) is a well-established treatment option for neuroendocrine tumors (NET), yet randomized controlled trials have not provided data on its impact on overall survival.
Annie Mathew, David Kersting, Wolfgang P. Fendler, Johanna Braegelmann, Dagmar Fuhrer, Harald Lahner   +5 more
doaj   +1 more source

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review

Frontiers in Endocrinology, 2022
PurposeTargeted radionuclide therapy (TRT) with [131I]MIBG and [177Lu]Lu-DOTA-TATE is an alternative treatment to the classic schemes in slow progressive metastatic/inoperable paraganglioma (PGL) and pheochromocytoma (PHEO).
Stefan Prado-Wohlwend, María Isabel del Olmo-García, Pilar Bello-Arques, Juan Francisco Merino-Torres, Juan Francisco Merino-Torres   +4 more
doaj   +1 more source

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

First results and experience with PRRT in South Africa

World Journal of Nuclear Medicine, 2018
Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs), which allows for positron emission tomography/computed tomography (PET/CT ...
Mariza Vorster, M Modiselle, C Corbett, I Lawal, John Buscombe, Mike Sathekge   +5 more
doaj   +1 more source

Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications

Frontiers in Oncology
Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors.
Martina Di Franco, Rexhep Durmo, Maria Liberata Di Paolo, Roberto Giacosa, Elisa Bannò, Valentina Ambrosini, Valentina Ambrosini, Angelina Filice   +7 more
doaj   +1 more source

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)

Microbiology Spectrum, 2022
As dolutegravir (DTG)-containing HIV regimens are scaled up globally, monitoring for HIV drug resistance (HIVDR) will become increasingly important.
Joshua DeVos, Kimberly McCarthy, Victor Sewe, Grace Akinyi, Muthoni Junghae, Valarie Opollo, Janin Nouhin, Robert Shafer, Clement Zeh, Artur Ramos, Heather Alexander, Joy Chang   +11 more
doaj   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, EarlyView.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +1 more source